能倍乐功效和作用

Respimat (Sriva) is a bronchodilator. Respimat (Sriva) is suitable for the maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, the maintenance treatment of accompanying dyspnea and the prevention of acute exacerbations. It can improve the quality of life of COPD patients and reduce acute exacerbations of COPD. In July 2018, Respimat (Siliva) was officially approved by the China Food and Drug Administration for long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD, referred to as COPD, including chronic bronchitis and emphysema) to relieve symptoms. What are the functions and effects?

Respimat efficacy and functions

COPD is a long-term lung disease that causes shortness of breath and coughing. Respimat (Seriva) helps open the airways, making it easier for air to move in and out of the lungs. Normal use of Respimat can also relieve persistent shortness of breath caused by the disease, helping to minimize the impact of the disease on daily life.

The approval of Respimat (Siliva) was based on data from two pivotal Phase III trials (TONADO-1, -2). The study involved more than 5,000 COPD patients. The data showed that compared with placebo, tiotropium bromide, and olodaterol monotherapy, Respimat (Seriva) caused a statistically significant improvement in patients' lung function (FEV1) and had a similar safety profile to tiotropium bromide or olodaterol.

Precautions for Respimat

Respimat (Sliva) spray is a colorless, clear liquid and can only be used by inhalation. The recommended dose for adults is to inhale once a day through the Respimat inhaler device at the same time, taking 2 puffs each time. Be careful not to overdose.

For elderly patients, there is no need to adjust the dosage of Respimat (Seriva). Patients with renal insufficiency and hepatic insufficiency can also use it at the recommended dosage, but it is best to do relevant monitoring. The safety of the drug is unknown and its use in pediatric patients under 18 years of age is not recommended.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended hot articles: